| abstract |
(57) Abstract The present invention relates to an isolated and purified cyclic peptide of 5 to about 13 residues, modeled on a part of the CS1 peptide. The peptide of the present invention preferably has the amino acid residue sequence of SEQ ID NOs: 2 to 14 or 16 to 42. The present invention further, alpha 4 beta 1 integrin, VCAM-1, relates to a method of selectively inhibiting the binding of proteins, such as fibronectin or invasin, the method, the presence of an inhibitory effective amount of the peptide, alpha 4 cells expressing beta 1 integrin including exposure to the protein. The invention further relates to a pharmaceutical composition comprising a physiologically acceptable carrier and a cyclic peptide of the invention. |